Analysts expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to report ($1.68) earnings per share (EPS) for the current quarter, according to Zacks. Eight analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($1.49) and the lowest estimate coming in at ($1.97). Ultragenyx Pharmaceutical reported earnings per share of ($1.74) in the same quarter last year, which indicates a positive year over year growth rate of 3.4%. The company is scheduled to announce its next quarterly earnings results on Monday, November 4th.

On average, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($6.72) per share for the current fiscal year, with EPS estimates ranging from ($7.42) to ($6.47). For the next fiscal year, analysts expect that the business will report earnings of ($5.21) per share, with EPS estimates ranging from ($7.36) to ($2.34). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.73) by $0.01. Ultragenyx Pharmaceutical had a negative return on equity of 49.84% and a negative net margin of 527.49%. The business had revenue of $24.15 million during the quarter, compared to analysts’ expectations of $22.16 million. During the same quarter last year, the business posted ($1.06) EPS. The business’s quarterly revenue was up 88.8% compared to the same quarter last year.

A number of brokerages recently issued reports on RARE. BidaskClub downgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday. ValuEngine cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a report on Thursday, September 5th. Wedbush reissued a “buy” rating and issued a $75.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Thursday, August 15th. Piper Jaffray Companies set a $75.00 price objective on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, Cowen reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the stock. Ultragenyx Pharmaceutical currently has an average rating of “Buy” and a consensus target price of $75.64.

In related news, CEO Emil D. Kakkis acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, September 11th. The stock was bought at an average price of $43.63 per share, for a total transaction of $218,150.00. Following the completion of the purchase, the chief executive officer now directly owns 472,479 shares of the company’s stock, valued at approximately $20,614,258.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Karah Herdman Parschauer sold 1,489 shares of the company’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $63.01, for a total transaction of $93,821.89. The disclosure for this sale can be found here. Corporate insiders own 7.80% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of RARE. Dimensional Fund Advisors LP lifted its holdings in shares of Ultragenyx Pharmaceutical by 120.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 136,555 shares of the biopharmaceutical company’s stock valued at $5,936,000 after purchasing an additional 74,608 shares during the last quarter. Geode Capital Management LLC grew its stake in Ultragenyx Pharmaceutical by 12.5% during the 4th quarter. Geode Capital Management LLC now owns 568,230 shares of the biopharmaceutical company’s stock worth $24,706,000 after buying an additional 63,118 shares during the last quarter. Strs Ohio increased its position in Ultragenyx Pharmaceutical by 235.3% during the first quarter. Strs Ohio now owns 5,700 shares of the biopharmaceutical company’s stock worth $395,000 after buying an additional 4,000 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Ultragenyx Pharmaceutical by 19.7% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,303 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 379 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Ultragenyx Pharmaceutical by 8.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,113 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 242 shares during the period.

Shares of RARE stock traded up $1.88 during trading hours on Friday, reaching $45.01. 1,933,591 shares of the stock were exchanged, compared to its average volume of 542,595. The business’s fifty day moving average is $55.85 and its two-hundred day moving average is $61.69. The firm has a market capitalization of $2.60 billion, a P/E ratio of -6.09 and a beta of 2.13. Ultragenyx Pharmaceutical has a 12-month low of $37.44 and a 12-month high of $90.98. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.32 and a quick ratio of 9.14.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Recommended Story: What does an outperform rating mean?

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.